John Boehner, who just a few years ago was two heartbeats away from becoming president of the United States, is now “all in on the cannabis industry,” which he promises can “quite possibly” be worth as much as “$1 trillion” in the near future.
And the Republican former speaker of the House of Representatives wants you to join him on this gravy train. All you need to do is buy the very exclusive stock tips that Boehner is now selling.
Marijuana stocks have been in a free fall over the past few days, with formerly blue-chip Canadian companies—which saw their shares swell in value in the run up to nationwide legalization so quickly it caught the eye of Mad Money’s Jim Cramer—suffering double-digit losses as amateur investors lose their nerve.
If Boehner shares their concern, he did not show it on Tuesday, when the erstwhile anti-marijuana lawmaker provided the star power for the launch of the National Institute of Cannabis Investors.
“This is the time,” Boehner solemnly said, “to go all in on cannabis.”
Boehner made waves earlier this year when he joined the board of advisors of Acreage Holdings, a New York City-based firm that says it runs medical marijuana dispensary and cultivation operations in 13 states. The company is now preparing to go public via a reverse takeover, plus plenty of internet hype.
That will presumably be very good news for John Boehner. In the meantime, the former speaker says he has other extremely good marijuana stock-related news to share with you—provided you pony up an untold sum of money for membership in the cannabis investors’ network.
Exactly which companies Boehner suggests you invest in in order to build “the kind of wealth that lasts for generations,” he did not say during Tuesday’s nearly hourlong “American Cannabis Summit,” an extended infomercial for the investors’ network, though he and his co-presenters—veteran stock-tip salesman Mike Ward and Danny Brody, who helped take public a Canadian marijuana company that recorded $0 in sales in fiscal year 2018 and had zero kilograms of product in their inventory as of July, according to Seeking Alpha—did drop some clues.
One company manufactures the plastic containers in which retail marijuana is packaged. Another makes legal CBD oil—because, as Boehner said, he’d “think twice” before offering someone medical cannabis with more than 0.15 percent THC. Yet another could “help end our devastating opioid epidemic,” Tuesday’s presentation promised.
One of these companies could be “38 times bigger than GW Pharmaceuticals,” the UK drug manufacturer with an FDA-approved cannabis-derived epilepsy medication. That’s a bold claim, but such is Boehner’s confidence. (It’s also backed by “not one, but two 100 percent money-back guarantees,” Ward said. So there is that.)
Other highlights from Tuesday’s tease:
There is “nobody in cannabis more connected in Washington” than Boehner, whose post-retirement preparation for the cannabis industry involved playing lots of golf, smoking cigarettes and ripping in-power Republicans, including the president.
Boehner knows exactly how President Donald Trump feels about marijuana legalization but won’t say, because “if I tell you about our private conversations, I won’t have any more of them.”
He does feel that federal legalization could happen within the next five years. “It’s not a matter of if, but a matter of when,” he said.
Because when has John Boehner ever been wrong about anything?
See the original article published on Marijuana Moment below:
John Boehner Is Now Selling Marijuana Stock Tips
Photo courtesy of Gage Skidmore.
An 8 year old girl will soon become the first person to legally use a medical cannabinoid medication in Mexico since the plant was declared illegal 90 years ago, following the International Opium Convention.
Grace Elizalde Benavides (photo below) suffers from a severe form of childhood epilepsy, known as Lennox-Gastaut syndrome, which causes her to suffer upwards of 400 seizures per day. Since the seizures started, Mayela, Grace’s mother reports that she has only gone backwards in development, and has an extremely poor quality of life.
The physicians treating Grace’s condition have prescribed every pharmaceutical medication on the market, and even performed a brain surgery on the young girl. Grace’s parents report that the holistic therapies they’ve tried have also been unsuccessful. Nothing so far has yielded positive results, and the Elizalde’s feel that medical marijuana is their last hope.
Cannabis, in all forms, is illegal in Mexico, so Grace’s parents have sought permission from the federal government to import cannabidiol oil. Cannabidiol, or CBD, is the non-psychoactive cannabinoid found in cannabis that has gained national media attention for its success in reducing the frequency and severity of symptoms in those suffering from epilepsy.
The federal government denied the Elizalde’s initial request for permission to import CBD oil, but an appeal to federal judge Martín Adolfo Santos Pérez earned them permission. The Mexican constitution provides citizens with the right to protect their health, so judge Pérez approved the family’s request on the grounds that they are protecting the health of their daughter.
While the Mexican government is not authorizing the importation of “marijuana in any of its forms,” the health ministry will permit them to import Epidiolex, a cannabinoid therapy medication produced by GW Pharmaceuticals of the United Kingdom. Epidiolex is a purified cannabis extract containing only the cannabinoid, Cannabidiol (CBD). It does not contain any amount of the psychoactive cannabinoid, Tetrahydrocannabinol (THC).
Relieved after receiving the good news, Grace’s father, Raul Elizalde told AFP,
“We are happy. It’s our last hope.”
“We want to reduce the number of convulsions from 400 per day to none. We hope that she could become more independent, that she could walk and speak and eat on her own.”
Raul met with Mikel Arriola, head of the Commission for Protection Against Sanitary Risk, on Tuesday. Arriola will facilitate administrative assistance necessary to import Epidiolex from either Norway or the United States.
Mikel Arriola (left) of Cofepris, and Grace’s father (right). Their signs read, ‘Everyone for Grace.’
photo credit: Adriana Zehbrauskas/For The Washington Post; Mexico News Daily
The first FDA-authorized clinical trial for a cannabis therapy medication, Epidiolex, is recruiting children with Dravet Syndrome, a severe form of epilepsy, to test the efficacy of the new drug. Epidiolex is a purified cannabis extract containing only the cannabinoid, Cannabibiol (CBD). It does not contain any amount of the psychoactive cannabinoid, Tetrahydrocannabinol (THC).
The trials, funded by Epidiolex producer, GW Pharmaceuticals, are being hosted by three different children’s hospitals in the United States. The first location is in Texas, center two is in Georgia, and the third is in Illinois. Each location is currently seeking to enroll ten participants between the ages of four and ten years old, for a total of thirty participants nationwide. In each set of ten participants, eight will be treated with Epidiolex, and two participants will be given a placebo instead. This phase of the trial will last for a total of twenty-one days. Out of thirty participants, twenty-four will be treated with one of three different dosage amounts of the CBD medication. The purpose of this phase of the study is to determine the ideal dosage for children suffering from Dravet Syndrome. This phase is anticipated to conclude before the end of the year.
Phase II of this clinical trial will be used to determine the safety and efficacy of long term use, once the appropriate dosage has been determined in Phase I. The second phase will increase participation from thirty to eighty children, and increase duration from three weeks to three months.
Texas Children’s Hospital was selected to be the trial location center in Texas, and Dr. Angus Wilfong, neurologist at the hospital, is the first physician in Texas certified to administer the medication, Epidiolex, to pediatric patients. Dr. Wilfong told KHOU11,
“As one of the largest epilepsy centers in the country, our focus has always been to find new and innovative ways to treat and cure children with various forms of epilepsy. Initial trials of Epidiolex have shown promising signals of efficacy in children with treatment- resistant epilepsy, and we are pleased to have the opportunity to partner with GW Pharmaceuticals in the first worldwide trial for this group of patients with such a catastrophic form of epilepsy.”
One of the patients, enrolled in the trial last week to be treated at Texas Children’s Hospital is six year old, Izaiah Ruiz, pictured below with his grandmother, Lori Fountain. Izaiah has a confirmed case of Dravet Syndrome, and suffers from daily seizures as a result. These daily seizures have caused Izaiah to develop at a much slower pace than other children who do not suffer from epilepsy. Developmentally, Izaiah is only about two years old. His grandmother, Lori, is also hopeful that this CBD medication may improve Izaiah’s quality of life.
She told KHOU11 that she is does not care what other people think about Izaiah’s participation in the study because she would try anything to give him the chance to live the life that most children are able to live, and grow to have a better quality of life as a teenager and eventually a man.
photo credit: Celebstoner, Houston Chronicle